Image (Dafad74d 98d3 4119 A9b0 4b45515698be 01)
Propafenone Hydrochloride Capsule, Extended Release
Product Images NDC 68382-522
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Propafenone Hydrochloride (NDC 68382-522). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Zydus Pharmaceuticals (usa) Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image (Dafad74d 98d3 4119 A9b0 4b45515698be 02)
This is a description of a clinical trial evaluating Propafenone ER at various doses over a period of 300 days. The results are presented in a table showing the amount of Propafenone ER and Placebo given on different days and the number of patients who experienced an event. The trial was discontinued on day 273 and one patient on 325 mg experienced an event on day 291 causing a 50% decline in Kaplan-Meier curves.*
Label (Dafad74d 98d3 4119 A9b0 4b45515698be 03)
This is the complete prescribing information for Propafenone Hydrochloride extended-release capsules. The medication should be stored at room temperature in a tightly closed container. The package is designed to be child-resistant, and it is important to keep all drugs out of the reach of children. The medication is manufactured by Cadla Healthcare Ltd in India and distributed by A Zydus Pharmaceuticals in the USA. No further relevant information is available due to errors.*
Label (Dafad74d 98d3 4119 A9b0 4b45515698be 04)
Propafenone Hydrochloride is a drug that comes in extended-release capsules containing 325 mg of propafenone hydrochloride. It is typically used as a prescription medication for controlling irregular heartbeats. The capsules come in a tight container, and the drugs should be kept out of the reach of children. Usual dosage instructions should be obtained from the package insert, and the capsules should be stored at 20° to 25°C. The manufacturer is Cadila Healthcare Ltd in India and is distributed by Zydus Pharmaceuticals (USA) Inc in Pennington, NJ.*
Label (Dafad74d 98d3 4119 A9b0 4b45515698be 05)
This is a description of a drug called Propafenone Hydrochloride Extended-release Capsules, which contains 425 mg of propafenone hydrochloride per capsule. The medication comes in a bottle with 60 capsules, manufactured by Cadia Healthcare Ltd in India and distributed by Zydus Pharmaceuticals (USA) Inc. The capsules should be stored at 20°C to 25°C and in a tightly sealed bottle. The usual dosage for this drug is not provided and should be reviewed in the package insert which provides the complete prescribing information. The package is child-resistant, and users are advised to keep it and all drugs out of the reach of children.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
